You have been chosen to receive this valuable information.

A SPECIAL
ANNOUNCEMENT FROM:

Face-to-face, Online training, and Certificate Programs available! Add Americas@DIAglobal.org.

Grow your knowledge, network with peers and experts, and make an impact on your business. Get Early Bird or Advance Rates during the month of September and save!

Oligonucleotide-Based Therapeutics Conference

From gene editing to immune stimulatory oligonucleotides, this conference covers the latest scientific and regulatory topics related to oligonucleotide-based therapeutics, as well as the barriers to successful synthesis and how to overcome them.

View Agenda

Examine the recent and ongoing changes in the regulatory ecosystem for combination product development and approval, and discover the key considerations used in determining appropriate regulatory submission globally.

Check Out a Preconference Short Course, offered Monday, October 28: "How Much is Enough? Best Practices and Principles for the Non-Lead Constituent Part Within a Regulatory Submission for a Combination Product."

Get Details

Measuring Impact in Patient-Centered Drug Development

How should organizations optimize patient engagement to ensure that processes are safe and provide value to all stakeholders? Gain industry insight into patient-centered approaches, outcome definition and criteria for success, and the evolution of regulatory metrics.

What to Know

Stay in the know with DIA Learning Solutions: face-to-face, online courses, certificate programs and group learning opportunities.

View Solutions

Email Preferences | Sign In

DIA | 800 Enterprise Road, Suite 200 | Horsham, Pennsylvania 19044-3595
T. +1.215.442.6100 or toll-free at +1.888.257.6457 | E. Americas@DIAglobal.org

Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Applied Clinical Trials, a MMH Group Publication. You are on the mailing list as %%emailaddress%%.